Aspen Bids To Acquire Sigma Pharma For A$1.5bn
Aspen is planning to acquire Sigma either directly or through a wholly-owned subsidiary. The amount set by Aspen includes A$707m in issued shares and A$785m in net debt,
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.